文献速递帕金森病与运动障碍

聚焦超声治疗运动障碍

Focused ultrasound therapy for movement disorders.
PubMed 文献 · Lancet Neurol · 2025-01-01

本文综述了磁共振引导聚焦超声(MRgFUS)作为无切口、微创神经功能治疗在运动障碍中的应用。随机对照试验已证实其热消融对特发性震颤和帕金森病的安全性和症状疗效,低强度超声的血脑屏障开放和神经调控也在探索中。

要点

  • MRgFUS热消融已获随机对照试验支持,用于特发性震颤和帕金森病。
  • 适应证正扩展至其他起源震颤和肌张力障碍,但属初步研究。
  • 低强度超声可实现短暂血脑屏障开放和神经调控,尚处实验阶段。

核心结论

  • MR引导聚焦超声可能在未来运动障碍和神经退行性疾病治疗中发挥重要作用。

研究设计与样本

  • 本文为综述,未报告系统检索范围;总结了随机对照试验及初步研究证据。

主要发现

  • 随机对照试验显示聚焦超声消融治疗特发性震颤或帕金森病具有安全性和症状疗效。
  • 聚焦超声治疗正扩展至全球许多中心,对其他适应证如其他起源震颤和肌张力障碍已有初步研究。
  • 低强度超声可对脑组织产生机械效应,主要是短暂血脑屏障开放和神经调控。

临床怎么用

  • 对于特发性震颤或帕金森病患者,MRgFUS消融可作为无切口、微创的功能神经外科治疗选择。

局限性

  • 对其他适应证如其他起源震颤和肌张力障碍的应用仅为初步研究。
  • 低强度超声的血脑屏障开放和神经调控仍处于实验和临床可能性探索阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Functional neurosurgery, such as deep brain stimulation, is an established therapeutic option for many patients with movement disorders. MR-guided focused ultrasound has emerged as an incisionless and minimally invasive neurofunctional treatment. This new approach is based on the delivery of high-intensity ultrasound energy to produce therapeutic thermoablation. Several randomised controlled trials have shown safety and symptomatic efficacy of focused ultrasound ablation, particularly to treat patients with essential tremor or Parkinson's disease. The use of focused ultrasound therapy is expanding to many centres worldwide, and its application for other indications-such as tremor of other origin and dystonia-has also been preliminarily investigated. MR-guided focused ultrasound has been explored in the modality of low-intensity ultrasound, which allows mechanical effects on brain tissue, primarily transient blood-brain barrier opening and neuromodulation, both of which could offer a wide array of experimental and clinical possibilities. Therefore, MR-guided focused ultrasound might have an important role in the future treatment of patients with movement disorders and neurodegenerative diseases.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Martínez-Fernández R, Paschen S, Del Álamo M, et al. Focused ultrasound therapy for movement disorders. Lancet Neurol. 2025. PMID: 40683278. doi:10.1016/S1474-4422(25)00210-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。